Advances in neonatal intensive care over the years have led to the survival of an increasing number of low birth weight (LBW, Յ1500 gm) neonates. The provision of intravenous nutrition for these high-risk neonates, who frequently do not tolerate enteral feeding, is essential for their growth and survival. Poor peripheral venous access is a frequent problem in the neonatal intensive care unit (NICU). This has led to the use of various types of central venous catheters (CVCs), in the hope that these would provide access that is more durable than peripheral intravenous catheters. CVCs, which can be inserted either surgically or percutaneously, are now an integral part of the intensive care that is provided for these neonates. CVCs often provide a means of vascular access that can last up to several weeks.
There are few articles that address the issue of CVC-related complications and associated risk factors in neonates, [1] [2] [3] especially LBW neonates. Differences in patient characteristics, such as birth weight, primary diagnosis, and the type of CVC used, also make comparisons between studies difficult. For example, in one large study, 4 most of the patients weighed Ͼ2000 gm, required surgical intervention for gastrointestinal malformations, and both percutaneous as well as surgically placed CVCs were utilized. It is uncertain whether percutaneous CVCs lead to fewer complications than surgically placed CVCs. When compared with larger neonates, the incidence of nosocomial sepsis appears to be increased in the LBW neonate with a CVC or an umbilical venous catheter. 5 It is unclear whether any other risk factors, apart from low birth weight, may also be important.
The primary objective of this study was to determine the incidence of complications in neonates Յ1500 gm birth weight who had a surgically inserted CVC. The secondary objective was to determine the risk factors that may be associated with sepsis and other complications.
METHODS

Background
Neonatal intensive care for south-central Ontario, Canada, is provided by three tertiary care units in Toronto: The Hospital for Sick Children (outborn unit), and Women's College and Mount Sinai Hospitals (both perinatal units). The NICU at The Hospital for Sick Children (HSC) accepts neonates for surgical insertion of CVCs from Women's College Hospital and Mount Sinai Hospital.
Central Venous Catheters
All CVCs were subcutaneously tunneled Roko catheters. These are manufactured from medical-grade silicone rubber. All CVCs were placed by pediatric surgeons in the operating room at HSC. Insertion was performed into a jugular vein using a standard technique, and the CVC was secured using a subcutaneous silicon rubber grommet. 6 Placement of the tip of the CVC in the distal superior vena cava (SVC) Original Article
was confirmed by an electrocardiographic method, as previously described. 7 The dressing at the CVC insertion site was initially changed on the third day following surgery, and then weekly, by NICU nurses. CVCs that were no longer required for the infusion of parenteral nutrition or medications were flushed with heparinized saline. CVCs were removed when it was felt that it was unlikely that they would be utilized, or if there were complications necessitating removal.
MATERIALS AND METHODS
All neonates with birth weights of Յ1500 gm who were born during the 5-year period, March 1, 1988 , to February 28, 1993 , and had a surgically inserted CVC were identified from a computer database maintained by the medical records department at HSC. Their hospital records at HSC as well as at the referring hospitals (Mount Sinai or Women's College Hospital) were reviewed. No patient was excluded.
Sepsis was defined as the combination of one or more signs and symptoms of sepsis (lethargy, apnea, feeding intolerance, and temperature instability), together with a positive culture from peripheral blood and/or a blood sample from the CVC. For the purposes of this study, only those episodes of sepsis that occurred when the CVC was in place were recorded. If sepsis occurred when the CVC was in place, it was routine to treat with antibiotics through the CVC. In the presence of sepsis, CVCs were removed if there was failure of resolution of symptoms and signs of sepsis or if alternate intravenous access was readily available. Other complications such as local infection, mechanical problems with the CVC, evidence of thrombosis, SVC syndrome, pleural effusions, and problems during surgery at the time of CVC insertion were also recorded.
Data Analysis
Statistical analysis was performed using SigmaStat for Windows 2.0. Associations were analyzed by the -squared statistic, odds ratio with 95% confidence intervals, and the two-tailed Student t test. Variables that had p values of Ͻ0.15 in univariate analyses were entered into a backward, stepwise regression analysis. Variables staying in the final regression model with a p value of Ͻ0.05 were regarded as exhibiting independent associations.
RESULTS
During the 5-year period, March 1, 1988 , to February 28, 1993, a total of 2934 patients of Յ1500-gm birth weight was admitted to the three NICU. One-hundred four patients (3.5%) had a total of 112 CVCs placed. The patient characteristics are shown in Table 1 , and the major diagnoses in Table 2 . Of note, 85 patients (82%) were of Յ1000-gm birth weight, whereas 19 were 1001 to 1500 gm. In 97 patients, the primary indication for CVC placement was for administration of parenteral nutrition, whereas, in the rest, it was for administration of antibiotics. In 43 neonates, the CVC was placed when other surgery, such as patent ductus arteriosus ligation, was being performed. All 112 CVCs were placed in the jugular veins: 84 in the right internal, 7 in the right external, 20 in the left internal, and 1 in the left external. The internal diameters of the CVCs were 0.025 inches in 41, 0.03 inches in 69, and 0.04 inches in 2.
Sepsis
Fifty-nine patients (57%) had one or more complication associated with the CVC, a rate of 27 complications/1000 catheter days (Table 3) . Sepsis was the commonest complication. There were 43 episodes of sepsis in 38 patients, resulting in 14.5 episodes/1000 catheter days. In those with sepsis the CVC was in place for a median of 28 days (range 7 to 130), compared with 18 days (range 1 to 83) in those without sepsis. For those with sepsis, the median duration of parenteral nutrition was 16 days (range 2 to 130), whereas, for those with no sepsis, it was 12 days (range 1 to 113 days). When univariate analyses were performed, associations with sepsis were birth weight ( p ϭ 0.015), male sex ( p ϭ 0.016), the duration for which the CVC remained in place ( p Ͻ 0.001), and duration of parenteral nutrition through the CVC ( p Ͻ 0.001). Sepsis was not associated with gestational age at birth, age, and weight at insertion of CVC, the duration for which the CVC was left unused, other surgical procedures, number of ventilator days, or death. Male patients were more likely to develop sepsis (odds ratio, 2.76; 95% confidence interval, 1.1 to 7.0). When backward, stepwise regression analysis was performed, the duration of parenteral nutrition through the CVC no longer remained as an independent association. Thus, in the final regression analysis, sepsis was associated with lower birth weight, male sex, and the duration for which the CVC remained in place.
Of the 43 episodes of sepsis, coagulase-negative staphylococci were isolated in 34 episodes (79%). Enterococcus was isolated in three, while Serratia, Staphylococcus aureus, ␣-hemolytic Streptococcus, Pseudomonas species, and Corynebacterium species were isolated in one episode each. Candida albicans was isolated in four episodes, and Malassezia furfur in one. All 43 episodes of sepsis were initially treated with antibiotics administered through the CVC. This approach was successful in treating the infection in most patients. In seven, however, the CVC was removed because of a failure of resolution of symptoms and signs of sepsis and persistence of positive blood cultures despite appropriate antibiotic therapy. Those with coagulasenegative staphylococcal infection were treated with a 7-to 10-day course of vancomycin, whereas those with fungal infection were treated with amphotericin.
Other Complications
Superior vena cava syndrome was diagnosed in five patients. This diagnosis was based on clinical findings of upper extremity edema and subsequent echocardiographic findings of thrombosis in the SVC. All were treated with heparin following the diagnosis. Two patients with SVC syndrome died, whereas in the others it resolved following treatment with heparin. Five patients (including one with SVC syndrome) developed pleural effusions, and three died. Of note, all nine patients who developed SVC syndrome and/or pleural effusions were Յ1000 gm birth weight, and five of these died.
Mechanical problems with blockage or breakage of the CVC occurred on 30 occasions. Urokinase instillation was successful in clearing 7 of 24 blocked CVCs. Five of six CVCs that cracked externally were successfully repaired using a repair kit. All 112 CVCs were eventually removed without any problems.
Outcomes
A total of 25 patients (24%) died, at a median age of 36 days (range 11 to 190). One patient had a birth weight of 1085 gm, whereas the rest were Յ1000 gm. There were eight deaths due to respiratory failure, seven due to necrotizing enterocolitis and its complications, and three in patients with congenital gastrointestinal anomalies. Two patients died because of sepsis while the CVC was in place, one from Candida sepsis, and the other due to Enterococcus. One patient died suddenly while a blocked CVC was being cleared with saline. This death may have occurred as a result of thromboembolism from the CVC. Four patients died as a result of various other causes. There was no difference in the incidence of death in those who developed sepsis as compared with those who did not. Follow-up data was available for 62 (78%) of the 79 patients who survived till discharge. At a median age of 12 (range 3 to 48) months, complications related to the CVC, such as SVC syndrome or wound breakdown, were not noted.
DISCUSSION
Nosocomial sepsis, a major problem in neonatal intensive care units, is associated with various factors, including low birth weight, the use of umbilical and central venous catheters, 5 and the infusion of parenteral nutrition. In LBW neonates, nosocomial sepsis prolongs hospital stay and is associated with increased morbidity and mortality. 8 Coagulase-negative staphylococci are the commonest organisms isolated in LBW neonates who develop nosocomial sepsis. In our cohort of neonates with CVCs, 79% of the episodes of sepsis were a result of coagulase-negative staphylococci.
In this cohort, one of the associations with sepsis was male sex. Although there was no difference in survival between males and females in this cohort, the association of poor neonatal outcome with male gender is well known. Moreover, mortality due to sepsis has been associated with male neonates, low birth weight, and prematurity. 9 The mean rates of umbilical or CVC-associated sepsis for the birth weight groups Յ 1000 gm and 1001 to 1500 gm have been reported by the National Nosocomial Infections Surveillance (NNIS) System to be 12.5/1000 and 5.3/1000 catheter days, respectively.
10 Our Յ1000-gm cohort had a comparable sepsis rate of 12/1000 catheter days. However, our 1001-to 1500-gm birth weight group had a sepsis rate of 23.8/1000 catheter days. This is considerably higher than the mean rate of 5.3/1000 and the 90th percentile rate of 17.2/1000 reported by the NNIS System. This may be related in part to a small sample size; there were only 19 patients in our 1001-to 1500-gm birth weight group. Differences in patient characteristics may also exist, but in the absence of comparable clinical details in the NNIS System study, these aspects can not be further explored. The reported incidence of sepsis with percutaneous CVCs, an alternative to CVCs, varies between 3 and 21.2/1000 catheter days. 11, 12 It is possible that scrupulous attention to hand-washing technique and CVC care may decrease the incidence of sepsis. 13 Administration of antibiotics via the CVC led to the resolution of sepsis in more than 80% of episodes in our cohort. This allowed continued use of the CVC, a major benefit for these babies who had poor peripheral venous access at the outset.
Out of necessity, CVCs are often placed in the smallest and the sickest of neonates. Although the mortality rate of 22% may appear to be high, this is probably due to the characteristics of the cohort. For example, 31 of the 114 patients (27%) had either NEC or a gastrointestinal malformation. In these high-risk patients, the occurrence of sepsis or death may also be related to their concomitant medical or surgical diagnosis. Clinically diagnosed neonatal thrombosis occurs infrequently, at a rate of 2.4/1000 neonatal intensive care admissions.
14 However, in those who develop this condition (excluding those with renal vein thrombosis), almost 90% are associated with an indwelling vascular catheter. 14 The site of CVC insertion may also influence the incidence of thrombosis. A rate of 28% has been reported for inferior vena cava cannulation, compared with 16.6% for SVC cannulation. 15 Thrombosis in association with CVCs may present with SVC obstruction and pleural effusions. 16 Pleural effusions may result from associated thoracic duct thrombosis. Furthermore, venous thrombosis may be related to the size of the CVC, with a disproportionately large CVC causing obstruction in a relatively small vein, or to 2-chloroethanol and ethylene oxide residues that result from gas sterilization of CVCs. 16 Moreover, preterm neonates appear to have a predisposition to disseminated intravascular coagulation and thrombotic complications, and have been shown to have a deficiency of protein C and antithrombin III. 17, 18 In our cohort, all nine patients who developed pleural effusions and/or SVC syndrome, had birth weights of Ͻ1000 gm. All those with SVC syndrome were treated with heparin. Three of those with pleural effusions required needle aspiration or chest tube drainage. Of the nine patients, five died. Pleural effusions and SVC obstruction appear to lead to increased morbidity and mortality. The addition of heparin to parenteral nutrition fluids may reduce the incidence of CVC-related thrombosis, and possibly infection. 19 Of note, during the period of this study, heparin was not routinely added to the parenteral nutrition fluids at the three hospitals. The use of heparin-bonded CVCs offers promise in reducing the incidence of both thrombosis and sepsis. 20 Although surgically inserted central venous catheters are capable of providing durable venous access in low birth weight neonates, there is a high incidence of complications associated with their use. In most patients, successful treatment of CVC-associated sepsis can be accomplished without sacrificing the CVC. However, as the incidence of SVC thrombosis and pleural effusions appears to be limited to those neonates who are of Ͻ1000-gm birth weight, surgically inserted CVCs should be used with caution in extremely low birth weight neonates. There remains a need for a large prospective trial comparing the different methods of venous access in neonates receiving intensive care.
